Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure

被引:29
|
作者
Broch, Kaspar [1 ,2 ,3 ]
Andreassen, Arne K. [1 ]
Ueland, Thor [4 ]
Michelsen, Annika E. [4 ]
Stueflotten, Wenche [1 ]
Aukrus, Pal [4 ,5 ]
Aakhus, Svend [1 ]
Gullestad, Lars [1 ,2 ,3 ]
机构
[1] Oslo Univ Hosp, Rikshosp, Dept Cardiol, N-0027 Oslo, Norway
[2] Univ Oslo, Fac Med, KG Jebsen Res Ctr, Oslo, Norway
[3] Univ Oslo, Fac Med, Ctr Heart Failure Res, Oslo, Norway
[4] Natl Hosp Norway, Internal Med Res Inst, Oslo 1, Norway
[5] Oslo Univ Hosp, Rikshosp, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway
关键词
Dilated cardiomyopathy; ST2; Hemodynamics; Etiology; Prognosis; EUROPEAN-ASSOCIATION; FAMILY-MEMBER; TRIAL; ECHOCARDIOGRAPHY; RECOMMENDATIONS; MORTALITY; RECEPTOR; SYSTEM;
D O I
10.1016/j.ijcard.2014.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elevated levels of soluble ST2 ( sST2) are associated with adverse outcome in heart failure. A change in sST2 levels has also been shown to presage outcome. In vitro, ST2 expression is induced by myocardial stress and pro-inflammatory stimuli. The determinants of sST2 levels in vivo, and how they vary with clinical status over time, have not been well described. In a cohort of patients with non-ischemic heart failure, we aimed to assess the association between sST2-levels and hemodynamic parameters reflecting right and left ventricular pre- and afterload, and how these vary with time and clinical status. Methods: We prospectively recruited 102 patients with a left ventricular ejection fraction of 26 +/- 10% and a diagnosis of idiopathic dilated cardiomyopathy based on patient history, clinical examination, echocardiography and coronary angiography. Patients went through extensive baseline work-up and were re-examined after one year. Subsequently, heart transplantations and deaths were recorded. Determinants of sST2 were analyzed at baseline and after one year. Soluble ST2 was measured with a highly sensitive immunoassay. Results: Soluble ST2 levels were associated with hemodynamic parameters, but these associations were attenuated with clinical improvement. Soluble ST2 was elevated in patients with severe symptoms, but did not vary with etiology, viral presence or the amount of myocardial fibrosis. Heart rate and right atrial pressure remained independent predictors of sST2 on multiple regression analysis. Conclusions: Our results imply that in non-ischemic heart failure, sST2 reflects hemodynamic stress rather than pathogenic processes in the myocardium. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 384
页数:7
相关论文
共 50 条
  • [1] Soluble ST2 in Heart Failure
    McCarthy, Cian P.
    Januzzi, James L., Jr.
    HEART FAILURE CLINICS, 2018, 14 (01) : 41 - +
  • [2] Soluble ST2 in heart failure
    Dieplinger, Benjamin
    Mueller, Thomas
    CLINICA CHIMICA ACTA, 2015, 443 : 57 - 70
  • [3] Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure
    Bayes-Genis, Antoni
    Pascual-Figal, Domingo
    Januzzi, James L.
    Maisel, Alan
    Casas, Teresa
    Valdes Chavarri, Mariano
    Ordonez-Llanos, Jordi
    REVISTA ESPANOLA DE CARDIOLOGIA, 2010, 63 (10): : 1171 - 1178
  • [4] Pulmonary Production of Soluble ST2 in Heart Failure
    Pascual-Figal, Domingo A.
    Perez-Martinez, Maria T.
    Asensio-Lopez, Maria C.
    Sanchez-Mas, Jesus
    Garcia-Garcia, Maria E.
    Martinez, Carlos M.
    Lencina, Miriam
    Jara, Ruben
    Januzzi, James L.
    Lax, Antonio
    CIRCULATION-HEART FAILURE, 2018, 11 (12) : e005488
  • [5] Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure
    Villacorta, Humberto
    Maisel, Alan S.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2016, 106 (02) : 145 - 152
  • [6] Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology
    Broch, Kaspar
    Ueland, Thor
    Nymo, Stale H.
    Kjekshus, John
    Hulthe, Johannes
    Muntendam, Pieter
    McMurray, John J.
    Wikstrand, John
    Cleland, John G.
    Aukrust, Pal
    Gullestad, Lars
    EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (03) : 268 - 277
  • [7] Soluble ST2 protein in chronic heart failure is independent of traditional factors
    Wojtczak-Soska, Karolina
    Pietrucha, Tadeusz
    Sakowicz, Agata
    Lelonek, Malgorzata
    ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (01) : 21 - 26
  • [8] Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure
    Manzano-Fernandez, S.
    Januzzi, J. L.
    Pastor-Perez, F. J.
    Bonaque-Gonzalez, J. C.
    Boronat-Garcia, M.
    Pascual-Figal, D. A.
    Montalban-Larrea, S.
    Navarro-Penalver, M.
    Andreu-Cayuelas, J. M.
    Valdes, M.
    CARDIOLOGY, 2012, 122 (03) : 158 - 166
  • [9] Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial
    Anand, Inder S.
    Rector, Thomas S.
    Kuskowski, Michael
    Snider, James
    Cohn, Jay N.
    CIRCULATION-HEART FAILURE, 2014, 7 (03) : 418 - U70
  • [10] Association of soluble ST2 with functional capacity in outpatients with heart failure
    Yucel, O.
    Gul, I
    Zararsiz, A.
    Demirpence, O.
    Yucel, H.
    Cinar, Z.
    Zorlu, A.
    Yilmaz, M. B.
    HERZ, 2018, 43 (05) : 455 - 460